Expert Interview
Delving into Altimmunes' pemvidutide and its potential use in Metabolic Dysfunction-Associated Steatohepatitis (MASH) prior to its 48 week IMPACT trial readout
Ticker(s): ALTInstitution: Northwest Hospital
- Gastroenterologist and VP of Medical Affairs at Northwest Hospital in Baltimore, Maryland
- Currently manages 50+ patients with MASH and over 100 GERD patients
- Clinical interest in GERD, polypectomy, and liver biopsy
How many patients with MASH do you manage in a month?
Added By: emily_adminIf approved, where do you do pemvidutide fitting into the current treatment space for MASH?
Added By: emily_adminWhat is your opinion on the data to date for pemvidutide ?
Added By: ben_adminHow do you interpret that pemvidutide shows strong MASH resolution and weight loss, but has not yet demonstrated statistically significant fibrosis improvement over placebo in prior studies?
Added By: ben_adminWhat are your thoughts on the 48 week data using non-invasive tests (NITs)?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
